NCT02172742View on ClinicalTrials.gov

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

July 31, 2002

Study Completion Date

July 25, 2002

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

BIA 2-093 1200 mg once-daily

DRUG

Placebo

matching placebo

DRUG

Digoxin

Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).

Trial Locations (1)

Unknown

Human Pharmacology Unit (UFH)Section of Clinical Research (SIC), Department of Research & Development (DID), BIAL - Portela & Cª, SA,, Trofa

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02172742 - The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin | Biotech Hunter | Biotech Hunter